DrugDashboards

Fluocinolone Acetonide

Fluocinolone Acetonide · FLUOCINOLONE ACETONIDE .25 mg/g · Ointment · Topical · ANI Pharmaceuticals, Inc.

NDC 62559-0299-60 · 1 TUBE in 1 CARTON / 60 g in 1 TUBE · NDA AUTHORIZED GENERIC · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 24% over the past year, to $0.5491 per gram. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.5491per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.7243per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$16.02per package of 60GMANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. · Jan 1, 2026

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 00713-0224-15) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.10per unit
middle half $1.01$1.32 · 5,362 plans · Apr 1, 2026
Est. net of rebates
≈ $1.10
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
98%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 64%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$0.5$1.00Jan 2024Sep 2026$0.5491
33 price points · per GMSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$84.53
Reported to Texas DSHS · 2026 annual filing · ANIP Acquisition Company

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$48,990
841 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

13Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 4 active manufacturers+5
  • price down 20% year over year+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for fluocinolone acetonide (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
NDA013960
TE code
AT
Approval date
Jan 1, 1982
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Fluocinolone Acetonide (Ointment)

LabelerStrengthFirst seenLast seen
ANI Pharmaceuticals, Inc.FLUOCINOLONE ACETONIDE .25 mg/gJul 15, 2026Sep 2, 2026
Cosette Pharmaceuticals, Inc.FLUOCINOLONE ACETONIDE .25 mg/gJul 15, 2026Sep 2, 2026
E. Fougera & Co. a division of Fougera Pharmaceuticals, LLCFLUOCINOLONE ACETONIDE .25 mg/gJul 15, 2026Sep 2, 2026
Medimetriks Pharmaceuticals, Inc.FLUOCINOLONE ACETONIDE .25 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Fluocinolone Acetonide — NDC 62559-0299-60," retrieved September 3, 2026, https://drugdashboards.com/drug/62559029960.

Free to cite with attribution — see how the data is put together.